BeiGene
BGNE
#959
Rank
โ‚ฌ18.65 B
Marketcap
170,47ย โ‚ฌ
Share price
0.49%
Change (1 day)
15.62%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total liabilities

Total liabilities on the balance sheet as of September 2024 : โ‚ฌ2.21 Billion

According to BeiGene 's latest financial reports the company's total liabilities are โ‚ฌ2.21 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

BeiGene - Total liabilities on balance sheet (from 2014 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31โ‚ฌ2.05 B10.26%
2022-12-31โ‚ฌ1.86 B-12.31%
2021-12-31โ‚ฌ2.12 B50.72%
2020-12-31โ‚ฌ1.40 B148.76%
2019-12-31โ‚ฌ0.56 B30.51%
2018-12-31โ‚ฌ0.43 B43.62%
2017-12-31โ‚ฌ0.30 B500.24%
2016-12-31โ‚ฌ50.29 M29.57%
2015-12-31โ‚ฌ38.81 M69.51%
2014-12-31โ‚ฌ22.9 M-37.4%
2013-12-31โ‚ฌ36.58 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
โ‚ฌ11.21 M-99.49%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ0.77 B-65.14%๐Ÿ‡บ๐Ÿ‡ธ USA